 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (KSF) are investigating the proposed sale of Timber Pharmaceuticals, Inc. (the...

TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR

NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Earthstone Energy, Inc. (NYSE: ESTE)s sale to ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ESTE, PR, TMBR

NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. (NYSE: TMBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TMBR to LEO Pharma A/S for (i) an initial upfront consideration of $14 million and (ii) up to an ...

Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL

Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ, Aug. ...

Timber Pharmaceuticals to be Acquired by LEO Pharma

NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the M&A Class Action Firm), a national securities firm ratedTop 50in the 2018-2021 ISS Securities Class Action Services Report and headquartered at theEmpire...

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CTG, TMBR, HEP, CEQP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR PR Newswire NEW YORK, Aug. 21, 2023 NEW YORK, Aug. 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ESTE, PR, TMBR

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Timber Pharmaceuticals, Inc. (NYSE: TMBR) to LEO Pharma A/S is fair to Timber shareholders. Halper Sadeh encourages Timber shareholders to click here to learn more about their legal rights and options or contact...

TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders

WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today ...

Timber Pharmaceuticals Discloses Communication From NYSE American

- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for Pediatric Dermatologys Annual Meeting - WARREN, NJ, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire ...

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire Timber Pharmaceuticals, Inc. ("Timber" or the Company) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the ...

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

Timber Pharmaceuticals, Inc. engages in the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases. The company was founded in 2019 and is headquartered in Warren, NJ.

Watchers	56,705
52-Wk Low	$1.20
52-Wk High	$6.20

Market Cap	$9.32M
Volume (M)	39,218.00
52-Wk High	$6.20
52-Wk Low	$1.20

TMBR Timber Pharmaceuticals Inc

About

Feed

News

Fundamentals